FY2025 EPS Estimates for TG Therapeutics, Inc. (NASDAQ:TGTX) Lowered by B. Riley

TG Therapeutics, Inc. (NASDAQ:TGTX) – Equities researchers at B. Riley cut their FY2025 earnings estimates for shares of TG Therapeutics in a research report issued on Wednesday, May 1st. B. Riley analyst M. Mamtani now expects that the biopharmaceutical company will earn $0.72 per share for the year, down from their prior estimate of $0.78. B. Riley has a “Buy” rating and a $29.00 price target on the stock. The consensus estimate for TG Therapeutics’ current full-year earnings is ($0.08) per share. B. Riley also issued estimates for TG Therapeutics’ FY2026 earnings at $1.53 EPS, FY2027 earnings at $2.54 EPS and FY2028 earnings at $3.46 EPS.

TG Therapeutics (NASDAQ:TGTX) last issued its earnings results on Wednesday, May 1st. The biopharmaceutical company reported ($0.07) earnings per share for the quarter, missing the consensus estimate of ($0.05) by ($0.02). The company had revenue of $63.47 million during the quarter, compared to analysts’ expectations of $54.60 million. TG Therapeutics had a return on equity of 33.79% and a net margin of 14.24%. TG Therapeutics’s quarterly revenue was up 713.5% on a year-over-year basis. During the same period in the previous year, the company earned ($0.28) EPS.

A number of other equities analysts have also commented on TGTX. JPMorgan Chase & Co. reiterated an “overweight” rating and issued a $25.00 price objective on shares of TG Therapeutics in a report on Thursday, April 18th. HC Wainwright increased their price target on TG Therapeutics from $45.00 to $49.00 and gave the company a “buy” rating in a report on Thursday. LADENBURG THALM/SH SH lifted their price objective on TG Therapeutics from $39.00 to $40.00 and gave the stock a “buy” rating in a report on Thursday. The Goldman Sachs Group increased their target price on TG Therapeutics from $12.00 to $13.00 and gave the company a “neutral” rating in a research note on Thursday, February 29th. Finally, StockNews.com lowered shares of TG Therapeutics from a “buy” rating to a “hold” rating in a research note on Saturday, February 24th. Two research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $29.83.

TG Therapeutics Price Performance

Shares of TGTX stock opened at $16.19 on Friday. The firm has a fifty day simple moving average of $15.25 and a 200-day simple moving average of $14.41. The company has a market capitalization of $2.50 billion, a PE ratio of 70.39 and a beta of 2.33. TG Therapeutics has a twelve month low of $6.46 and a twelve month high of $35.67. The company has a current ratio of 5.92, a quick ratio of 5.18 and a debt-to-equity ratio of 0.62.

Insider Activity at TG Therapeutics

In other news, Director Laurence N. Charney sold 22,000 shares of the firm’s stock in a transaction dated Tuesday, March 12th. The shares were sold at an average price of $15.97, for a total value of $351,340.00. Following the transaction, the director now directly owns 215,229 shares in the company, valued at approximately $3,437,207.13. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Corporate insiders own 9.20% of the company’s stock.

Hedge Funds Weigh In On TG Therapeutics

Institutional investors have recently made changes to their positions in the stock. Assenagon Asset Management S.A. acquired a new position in shares of TG Therapeutics during the third quarter valued at $1,219,000. Hussman Strategic Advisors Inc. bought a new stake in TG Therapeutics in the 3rd quarter valued at about $439,000. Rhenman & Partners Asset Management AB boosted its stake in TG Therapeutics by 190.9% during the 3rd quarter. Rhenman & Partners Asset Management AB now owns 160,000 shares of the biopharmaceutical company’s stock valued at $1,338,000 after purchasing an additional 105,000 shares during the period. Rafferty Asset Management LLC grew its position in TG Therapeutics by 183.2% in the 3rd quarter. Rafferty Asset Management LLC now owns 856,837 shares of the biopharmaceutical company’s stock worth $7,163,000 after purchasing an additional 554,309 shares during the last quarter. Finally, Blueshift Asset Management LLC acquired a new stake in shares of TG Therapeutics in the third quarter valued at approximately $511,000. 58.58% of the stock is owned by institutional investors.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.